Ghost Tree Capital’s Amicus Therapeutics FOLD Stock Holding History

Ghost Tree Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-100,000	Closed	-$970K	–	58
2015 Q4	$970K	Buy	+100,000	New	+$901K	0.4%	43

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ghost Tree Capital's FOLD Position: Q4 2023 in Review

Ghost Tree Capital sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 175,000 shares — an estimated $2.13M sold.

Ghost Tree Capital first reported a position in FOLD in Q2 2014 and held it in 23 quarters. The position peaked at $18.1M in Q2 2019. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

Ghost Tree Capital reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 175,000 Amicus Therapeutics shares in Q4 2023, an estimated $2.13M.
Ghost Tree Capital first reported a position in Amicus Therapeutics in Q2 2014 and held it in 23 quarters.
Ghost Tree Capital's Amicus Therapeutics position peaked at $18.1M in Q2 2019.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.